How CRISPR Is Revolutionizing Cancer Research

On Demand

Summary

CRISPR/Cas9 is a game-changer in cancer research. In recent years it has enabled dramatic advances in our understanding of cancer genetics. Researchers have used this technology to study how genomic alterations in cancer impact tumor initiation, growth, and drug responses.

Join Associate Professor Monte Winslow to explore the many ways genome editing can help us determine which mutations drive cancer development. Drawing insights from his own laboratory and examples from current literature, he will show how this technology has revolutionized our ability to study and treat this disease more efficiently and effectively.

You Will Learn:

The basic mechanisms of CRISPR/Cas9 genome editing technology
Innovative methods for uncovering gene function in living organisms
How genome editing can be used to modify panels of genes in parallel
Item 4

Presented By

The Genetics and Genomics Program program.

Questions?

[email protected] | 650-204-3984

UTM_source:

utm_campaign:

utm_medium:

utm_content:

SIC Code:

First Name

Last Name

Share this webinar

CTA BTN

Speakers

Officia Deserunt

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Officia Deserunt

Monte Winslow

Dr. Winslow grew up in Canada and received his undergraduate degree from the University of Victoria, Canada. He did his PhD studies in Immunology working with Dr. Jerry Crabtree at Stanford University before pursuing his postdoctoral training with Dr. Tyler Jacks at MIT. Dr. Winslow is currently an Associate Professor of Genetics and Pathology at Stanford University.

Dr. Winslow’s research focuses on understanding the mechanisms that drive cancer development, progression, metastasis, and therapy response. He has developed in vivo mouse models to enable the isolation and genomic characterization of cancer cells and used these models to contribute to our understanding of cancer initiation, growth, and progression. These studies have focused on uncovering the molecular forces that contribute to the development and progression of three of the most metastatic and deadly cancer types: lung adenocarcinoma, small cell lung cancer, and pancreatic cancer. He has also contributed to the development of novel cancer modeling approaches that enable rapid and quantitative analyses of the genetic drivers of carcinogenesis. His laboratory has generated methods for somatic CRISPR/Cas9-mediated genome editing and used these models to induce both gain- and loss-of-function alterations in somatic cells in vivo. By incorporating increasingly quantitative methods and powerful in vivo methods, Dr. Winslow’s work is uncovering general rules that govern tumor initiation, growth and progression across diverse tumor genotypes.

Officia Deserunt

Stanford Online Innovation & Design Thinking Cybersecurity Artificial Intelligence Digital Transformation Health & Medicine Environment & Energy